DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d40cf4/il1_signaling_pat) has announced the addition of the "IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2011" report to their offering.
The IL-1 signaling pathway activates the MAPK/JNK signaling modules. The MAPK pathway leads to activation of NFkB complex. As both IL-1 and TNF alpha stimulate the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 53 companies plus partners developing 42 IL-1 pathway targeting drugs in 162 developmental projects in cancer.
In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 23 drugs. Il-1 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 44 different targets. These targets are further categorized on in the software application by 18 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.
Find and sort drugs by twelve different parameters plus free text search field. Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser, whether it is a single drug profile or an entire search you want have a report of.
This pipeline update includes more than 53 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators. This Drug Pipeline Update contains 42 IL-1 pathway targeting drugs in development, which have a total of 162 developmental projects in cancer. In addition there are suspended and ceased drugs.
For more information, including a more detailed table of contents, visit http://www.researchandmarkets.com/research/d40cf4/il1_signaling_pat
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
For more information visit http://www.researchandmarkets.com/research/d40cf4/il1_signaling_pat